Abschluss eines nicht exklusiven Rabattvertrages nach§ 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Trastuzumab, ausgenommen Rezepturen (ATC-Code: L01FD01) innerhalb des Zeitraumes vom 01.11.2026 bis zum 31.10.2028 mit jederzeitiger Möglichkeit des Vertragsabschlusses während der Laufzeit („open-house-Modell“).

TENDER DESCRIPTION

AOK Niedersachsen. The health insurance fund intends to enter into non-exclusive pharmaceutical rebate agreements for the active ingredient Trastuzumab, excluding formulations (ATC code: L01FD01), with as many market participants as possible (pharmaceutical entrepreneurs or associations of pharmaceutical entrepreneurs) under the so-called “open-house model”, until the entry into force of exclusive contracts following a public tender in accordance with the provisions of Part 4 of the GWB. AOK Niedersachsen will not make a selection decision and will submit an identical contract offer to every interested pharmaceutical company. In the open-house model, uniform conditions apply to all participants. Contract contents, terms and conditions, and access procedures are uniform—individual negotiations are generally not conducted. The agreement terms are a maximum of twenty-four months; the earliest possible start date is 01.11.2026. All agreements end at the latest on 31.10.2028, regardless of the date on which the respective agreement is concluded. Entry into an agreement or conclusion of an agreement may take place within the twenty-four-month period, each time on the first day of a…

TENDER BRIEF

TENDER DOCUMENTS